Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (CRL)

Market Closed
17 Apr, 20:00
NYSE NYSE
$
106. 05
+1.8
+1.73%
$
10.18B Market Cap
- P/E Ratio
0.4% Div Yield
1,658,400 Volume
- Eps
$ 104.25
Previous Close
Day Range
102.65 106.23
Year Range
91.86 254.15
Earnings results expected in 16 days

Summary

CRL closed Thursday higher at $106.05, an increase of 1.73% from Wednesday's close, completing a monthly decrease of -29.68% or $44.76. Over the past 12 months, CRL stock lost -43.26%.
CRL is not paying dividends to its shareholders.
The last earnings report, released on Feb 12, 2025, exceeded the consensus estimates by 0.13%. On average, the company has surpassed earnings expectations by 0.23%, based on the last three reports. The next scheduled earnings report is due on May 07, 2025.
The stock of the company had never split.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track CRL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

CRL Chart

Charles River Laboratories International, Inc. (CRL) FAQ

What is the stock price today?

The current price is $106.05.

On which exchange is it traded?

Charles River Laboratories International, Inc. is listed on NYSE.

What is its stock symbol?

The ticker symbol is CRL.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 10.18B.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on May 07, 2025.

Has Charles River Laboratories International, Inc. ever had a stock split?

No, there has never been a stock split.

Charles River Laboratories International, Inc. Profile

Diagnostics & Research Industry
Healthcare Sector
Mr. James C. Foster J.D. CEO
NYSE Exchange
US1598641074 ISIN
United States Country
20,400 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Charles River Laboratories International, Inc. stands as a pivotal organization within the pharmaceutical industry, providing a comprehensive suite of services encompassing drug discovery, non-clinical development, and safety testing. With a global footprint that extends across the United States, Europe, Canada, the Asia Pacific, and other international markets, the company is recognized for its integrated solutions that support the entire drug development cycle. It operates through three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing), each tailored to meet the varied and complex needs of its clients. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories is dedicated to aiding its clients in the development of novel therapies and medicines through its vast expertise and comprehensive facilities.

Products and Services

Research Models and Services (RMS): This segment is integral to Charles River Laboratories' operations, producing and selling a wide variety of research rodents, including purpose-bred rats and mice. These are essential tools for researchers across the globe, enabling a myriad of scientific investigations and discoveries. Services offered within this segment also include:

  • Genetically Engineered Models and Services: Customization and production of genetically modified animals to meet specific research requirements.
  • Insourcing Solutions: Provision of skilled personnel and resources to manage and operate clients' laboratory animal facilities.
  • Research Animal Diagnostic Services: Comprehensive diagnostic services to ensure the health and genetic integrity of research models.

Discovery and Safety Assessment (DSA): A critical segment that supports early-stage drug discovery and safety assessment. The DSA segment delivers:

  • Early and in vivo Discovery Services: Identification and validation of novel targets, chemical compounds, and antibodies, alongside the delivery of preclinical drug and therapeutic candidates ready for safety assessment.
  • Safety Assessment Services: Extensive testing services including toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics to ensure candidate drugs are safe for clinical trials.

Manufacturing Solutions (Manufacturing): This segment provides critical support in the quality control and testing of pharmaceuticals and consumer products. It encompasses:

  • In vitro Methods for Quality Control: Testing services for both sterile and non-sterile pharmaceuticals and consumer products, including specialized testing of biologics outsourced by pharmaceutical and biotechnology companies.
  • Contract Vivarium Operation Services: Operational support for biopharmaceutical clients’ vivarium facilities, ensuring the maintenance of high-quality standards in animal care and research.

Contact Information

Address: 251 Ballardvale Street
Phone: 781 222 6000